Author: CAPD

Economist Alex Brill in Q&A With Carol Vassar on Drug Companies’ Anticompetitive Behavior

On October 1, Matrix Global Advisors’ CEO Alex Brill joined POLITICO health care contributor and podcast host Carol…

Medicare Part D Enhancements that Would Deliver Savings & Choice, Not Higher Premiums for Seniors

It’s widely agreed that Medicare Part D is one of the most successful public-private partnerships, delivering affordability and…

New Report Quantifies the Harm of Product Hopping to Patients and the U.S. Health Care System

Product hopping is a practice commonly used by pharmaceutical companies to extend the life of their patents, and…

Seniors, Taxpayers Will Face Billions in Higher Drug Costs Without Rebates

President Trump has signed an Executive Order to eliminate drug rebates in Medicare Part D, after the Administration…

New Data: American Seniors and Voters are Very Concerned About the Prospect of No Rebates & Higher Costs in Medicare Part D

The Trump Administration recently announced an Executive Order to implement the “Rebate Rule” and eliminate rebates in Medicare…

Georgia Legislators Should Preserve Tools to Lower Drug Prices

Published in The Newnan Times-Herald As COVID-19 continues to impact the nation, Georgia’s Governor and state legislature are…

New Study Shows Big Pharma’s Prices Push Drug Costs Higher

Anyone following the U.S. drug pricing debate knows that “drug prices” are complicated. Most brand-name prescription drugs sold…

Tapping into the Generic Pipeline in 2020: Savings for Consumers

Three months into 2020 and the prescription drug pricing crisis continues to grow; in January alone, drug manufacturers…

Drug Pricing: Questions for the Presidential Candidates

With the Iowa caucuses and New Hampshire primary taking the spotlight, national attention on the presidential race and…

Creating a Competitive Marketplace that Works for Patients

U.S. patients, payors and the health care system are spending billions of dollars more on prescription drugs than…